Efinaconazole (Jublia) for the treatment of onychomycosis.
Efinaconazole 10% nail solution (Jublia(®)) is a new topical triazole antifungal designed for the topical treatment of distal and lateral subungual onychomycosis. It inhibits ergosterol biosynthesis enzyme sterol 14α-demethylase. Efinaconazole has lower minimum inhibitory concentrations than terbinafine, ciclopirox, itraconazole and amorolfine in Trichophyton rubrum, Trichophyton mentagrophytes and Candida albicans. The solution based formula has low surface tension and keratin binding properties that increase penetrance through the nail plate. Safety studies have shown that this formulation is not associated with atopic dermatitis or contact sensitivity. Duplicate Phase III clinical trials in adults with mild to moderate distal and lateral subungual onychomycosis indicate that efinaconazole 10% solution is an effective therapy with a pooled complete cure rate of 17% and a pooled mycological cure rate of 54%. Efinaconazole 10% nail solution is a safe and effective new topical therapy for onychomycosis, which will fill a pressing need for more effective topical therapy in this disease.
Mediprobe Research Inc., 645 Windermere Rd., London, ON, Canada.
Aditya K
AK
Gupta
Fiona C
FC
Simpson
D058888:14-alpha Demethylase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D000287:Administration, Topical; D002986:Clinical Trials as Topic; D004875:Ergosterol / Q000096:biosynthesis; D006801:Humans; D008826:Microbial Sensitivity Tests; D014009:Onychomycosis / Q000188:drug therapy*; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*
D058888:14-alpha Demethylase Inhibitors; D014230:Triazoles; C431707:efinaconazole; D004875:Ergosterol
azole; dermatophyte; efinaconazole; non-dermatophyte mold; onychomycosis